MFDS
- Status: likely_approved
🇰🇷 Rydapt in South Korea
Rydapt (MIDOSTAURIN) regulatory status in South Korea.
Marketing authorisation
Rydapt in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in South Korea
Frequently asked questions
Is Rydapt approved in South Korea?
Yes. MFDS has authorised it.
Who is the marketing authorisation holder for Rydapt in South Korea?
Novartis is the originator. The local marketing authorisation holder may differ — check the official source linked above.